• Mashup Score: 0
    Venetoclax and navitoclax for R/R ALL and lymphoblastic lymphoma - 3 year(s) ago

    Despite the development of novel therapeutic and chemotherapeutic agents, a great percentage of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) respond badly to treatment and have poor prognosis.

    Source: lymphomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      In case you missed it ✅ During #EHA25Virtual, Elias Jabbour presented results from a phase I trial investigating the combination of venetoclax and navitoclax for pediatric and adult R/R ALL and LL. Read a summary here ➡️ https://t.co/U6wn0MiIxB #lymsm https://t.co/KUF6smQgxO

  • Mashup Score: 0
    QUAZAR AML-001 | Updates from EHA 2020 - 3 year(s) ago

    The QUAZAR AML-001 study (NCT01757535) has uncovered the significant clinical activity of CC-486 maintenance in patients aged ≥ 55 with acute myeloid leukemia (AML), in first remission following induction chemotherapy and who were not eligible for hematopoietic stem cell transplantation (HSCT).

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      Read a summary of the data from this analysis as reported by Gail Roboz at #EHA25Virtual on the @AML_Hub ⬇️ https://t.co/x1upjtX7eH #leusm

  • Mashup Score: 0
    Lymphoma Daily - 4 year(s) ago

    Content directly from sources and does not necessarily reflect my views by Jason R Westin

    Source: paper.li
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Lymphoma_Doc
      Lymphoma_Doc

      The latest Lymphoma Daily! https://t.co/X1m1tYU1bE Thanks to @OrlaithClinton #prayfordan #eha25virtual

  • Mashup Score: 0
    Update from EHA 2020: Targeted therapy in CLL - 4 year(s) ago

    During the 25th European Hematology Association (EHA) Annual Congress, the Lymphoma Hub was pleased to speak to Steering Committee Member Astrid Pavlovsky, Fundaleu CHP, Buenos Aires, AR, about targeted therapy in CLL.

    Source: lymphomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      📽️ Watch the @lymphomahub interview, with the Steering Committee member Astrid Pavlovsky, on targeted therapy in #CLL, here: https://t.co/67BIBYlpEj #lymsm #EHA25Virtual https://t.co/s4Xb03aHuY

  • Mashup Score: 1
    Update in HL from EHA 2020 - 4 year(s) ago

    Astrid Pavlovsky discusses two major topics when considering the treatment of Hodgkin lymphoma. Firstly, she outlines the latest on PET/CT-adapted treatments in the frontline setting, and secondly, she discusses the refinement and consolidation of combination regimens for the treatment of Hodgkin lymphoma.

    Source: lymphomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      During #EHA25Virtual our Steering Committee member Astrid Pavlovsky discussed the updates in the treatment of Hodgkin #lymphoma. Watch the interview on the @lymphomahub 👉 https://t.co/XX1nnEMW7R #lymsm https://t.co/lQonfoZKuI

  • Mashup Score: 2
    Second primary malignancy after treatment with ruxolitinib - 4 year(s) ago

    Francesca Palandri, PhD, MD, University Hospital, Bologna, Italy, explores the incidence of second primary malignancies after treatment with ruxolitinib. This…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      VIDEO: How does ruxolitinib treatment effect second primary malignancies w/ Francesca Palandri of University of Bologna: https://t.co/7wiVmIZBRf @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert

  • Mashup Score: 1
    The evolving CLL treatment paradigm - 4 year(s) ago

    Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, highlights novel targeted therapies in development for chronic lymphocytic leukemia…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Video: The evolving #CLL treatment paradigm explained by Carsten Niemann of @uni_copenhagen: https://t.co/G5dCK9fZsm @VJHemOnc @EHA_Hematology #EHA25 #HemOnc #Oncoalert #EHAtrending #EHA25Virtual @OncoAlert #Leusm #Leukemia

Load More